^
Association details:
| Biomarker: | GZMB elevation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
Published date:
05/26/2020
Excerpt:
"Patients with low baseline serum levels of granzyme B had a significant worse PFS (HR: 1.96; 95%CI: 1.12 to 3.43; p=0.018, figure 1A) than patients with high levels of baseline serum granzyme B. . Likewise, low levels of granzyme B were significantly associated with worse OS (HR: 2.08; 95%CI: 1.12 to 3.87; p=0.021, figure 1B) compared with high levels of granzyme B.
DOI:
10.1136/jitc-2020-000586
